Fjarde AP Fonden Fourth Swedish National Pension Fund Has $5.95 Million Stock Position in Illumina, Inc. $ILMN

Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 45.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 48,286 shares of the life sciences company’s stock after acquiring an additional 15,100 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Illumina were worth $5,952,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Capital World Investors raised its position in Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. Invesco Ltd. raised its position in shares of Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after acquiring an additional 1,352,731 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after acquiring an additional 1,028,099 shares during the period. Morgan Stanley boosted its holdings in Illumina by 66.0% in the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after acquiring an additional 1,005,474 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in Illumina by 2,792.2% in the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of ILMN stock opened at $188.68 on Monday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $189.46. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The firm has a fifty day moving average of $154.74 and a 200-day moving average of $139.45. The company has a market capitalization of $28.55 billion, a price-to-earnings ratio of 34.31, a P/E/G ratio of 3.53 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the firm posted $0.97 EPS. The firm’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent research reports. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Piper Sandler increased their target price on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 1st. Barclays boosted their target price on Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a research report on Wednesday, June 24th. Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Guggenheim upped their target price on shares of Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus target price of $148.94.

Insider Buying and Selling at Illumina

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at $2,311,360. The trade was a 3.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.